For a patient treated with abiraterone for first line metastatic prostate cancer, would you still use a combination of abiraterone/olaparib at a subsequent progression?
If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?
Community PollStarted
For a BRCA+ patient who received abiraterone + ADT in hormone sensitive metastatic prostate cancer, would you go on to use abi/olaparib combination in CRPC?
65 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
No, there is no evidence for this, and in the absence of benefit, I would use single agent olaparib in HRD+ patients only, particularly BRCA2 patients. Ongoing trials like the CASPAR trial will address this question. In addition, there are ongoing trials testing PARP/AR combinations in men with mHSP...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · UTSouthwestern Medical Center
Answered on
This was not the PROpel population – if abiraterone was continued from the metastatic hormone sensitive setting to the metastatic castration resistance setting, I don’t think adding Olaparib directly to abiraterone will salvage the abiraterone resistance.
Join for free or sign in to see the full answer